Pharma

Shire’s Xiidra “Important” Addition to Dry Eye

By Tom Salemi | July 13, 2016

Two years ago, Robert Dempsey joined Shire to build the pharma giant’s new ophthalmology unit. Rather than acquire a portfolio of established products to build…

Read More
Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Can Ocular Therapies Diversify Biogen Portfolio?

By Michelle Dalton | June 29, 2016

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…

Read More
What’s Next for Acucela? Wait and See - Eye On Innovation Article - OIS - Healthegy

What’s Next for Acucela? Wait & See

By Rich Kirkner | June 22, 2016

Now that Acucela and Otsuka Pharmaceutical of Japan have torn up their collaborative deal to develop emixustat, which failed to meet its primary endpoint in…

Read More
Stem Cell Therapies for AMD Making Strides - Eye On Innovation Article - OIS

Stem Cell Therapies for AMD Making Strides

By Michael Smolinsky | June 15, 2016

In 2013, the first clinical study of stem cells in ophthalmology set high hopes that companies may one day develop cell-based therapies for neovascular age-related…

Read More
Omeros Sees the Corner and Is Ready to Turn - Eye On Innovation Article - Healthegy

Omeros Sees the Corner & is Ready to Turn

By Rich Kirkner | May 31, 2016

A year out from getting US approval of its Omidria agent for cataract surgery, Omeros has bulked up its sales force in anticipation of a…

Read More
Mixing MIGS and Meds - Eye On Innovation Article

Mixing MIGS & Meds

By Michelle Dalton | May 3, 2016

Long gone are the days where glaucoma surgery meant an invasive procedure with the likelihood of a serious complication developing down the road – while…

Read More
Iridex Makes Its Move in Glaucoma - Eye On Innovation Article

Iridex Makes its Move in Glaucoma

By Larry Haimovitch | April 27, 2016

Over the past couple of years, there has been no shortage of positive news about the glaucoma space. While minimally invasive glaucoma surgery (MIGS) has…

Read More
Avedro Finally Secures FDA Approval - Eye on Innovation Article

Avedro Finally Secures FDA Approval

By Tom Salemi | April 19, 2016

On Monday, Avedro Inc. announced the US Food and Drug Administration finally gave a green light for its KXL System in corneal collagen cross-linking for…

Read More
Outlook for Combination Therapies in Retinal Disease - Eye on Innovation

Outlook for Combination Therapies in Retinal Disease

By Michael Smolinsky | April 13, 2016

When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea)…

Read More
With Pfizer Deal, Allergan Looks Ahead: Could B+L Be In Its Sights? - Eye on Innovation

Without Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?

By Rich Kirkner | April 6, 2016

Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is…

Read More
OIS - Eye on Five

Eye on Five – March Edition

By Rich Kirkner | March 31, 2016

Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody…

Read More
The Biosimilars Race for AMD Treatments Is On - Eye on Innovation

The Biosimilars Race for AMD Treatments Is On

By Rich Kirkner | March 29, 2016

Formycon, the German-based developer of biosimilar agents, may be getting a leg up in the race to develop biosimilars for intravitreal anti-VEGF agents as it…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.